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Abstract. We describe a PCR based method for qualitative 
and quantitative analysis of the Η-ras gene. For qualitative 
analysis the aim was to detect codon 12 point mutations at 
transcriptional and genomic levels by a non-radioactive 
RFLP assay. Quantitative analysis was achieved by 
constructing an internal competitor with the same primer site 
requirements and sequence homology to the H-ras 1 gene. 
The internal control was cloned into an expression vector 
allowing quantification at the genomic as well as 
transcriptional level. Two cell lines harbouring normal and 
T24 H-ras 1 respectively, were employed as controls for 
qualitative and quantitative analysis. Theoretical implications 
of competitive quantification are also evaluated for increased 
estimation efficiency. 
Introduction 
ras oncogenes have been found to play an important role in 
the multistep process of carcinogenesis, ras gene activation 
either through structural modifications and/or alterations of 
gene expression levels can lead to loss of normal control of 
cell growth and differentiation (1,2). 
Activation through point mutations of ras genes has been 
found to be an early and influential event during the initiation 
and progression of many cancers (1-4). However, recent 
work has emphasised the importance of gene dosage on the 
phenotype of cells bearing ras oncogenes (5). Furthermore, 
analysis of expression levels in late stages of colorectal 
tumours, has shown that there is an imbalance between 
mutant versus normal K-ras alleles at the RNA level (6). 
These observations suggest that the capacity of ras to 
influence tumorigenesis is not restricted to point mutational 
activation affecting early stages of malignant progression. On 
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PCR-RFLP 
the contrary, altered ratios of ras genes at either gene level, 
transcriptional or post-transcriptional level can also 
apparently affect progression in later stages of tumour 
development. 
We have designed a reverse transcription-competitive 
PCR-RFLP assay in order to detect codon 12 point mutations 
at the DNA and RNA level and also to quantitate differences 
between the expression of mutant and normal H-ras 1 alleles. 
This allows the detection not only of early activating 
mutations, but also changes in gene dosage during 
subsequent stages of tumour evolution. 
The PCR products from DNA and RNA amplifications 
are 419bp and 151 bp respectively. Two natural Mspl 
restriction sites present in both PCR products of the normal 
gene, facilitate the detection of codon 12 mutations and 
discrimination between normal and mutant alleles (7). 
For quantitative studies a construct derived from the 
DNA PCR product after internal deletion of 187 bp, was 
cloned into an expression vector. Products from this DNA 
could thus be distinguished by size from those produced from 
genomic DNA and cDNA. After in vitro transcription the 
cRNA is employed as an internal standard during the RT-
PCR quantitative assay, while the construct itself is used as a 
standard for genomic DNA quantitation. The simultaneous 
coamplification of the standard corrects for the differences in 
the PCR amplifications which can occur in each test tube. 
This is simplified by the use of a single pair of PCR primers 
and results in competitive coamplification of all types of 
transcripts. 
The method described in this report was applied to cell 
lines: RFH06N1 and RFAGT1 (8,9). RFH06N1 and 
RFAGT1 were obtained after transfecting high copy numbers 
of normal and T24 H-ras 1 gene respectively into 208F rat 
fibroblasts, both express high levels of ras p21 (8,9). We 
were able to detect the specific type of H-ras 1 allele present 
in each cell line and to estimate the H-ras 1 copy numbers 
both at genomic and transcriptional level in each cell line 
respectively. 
Materials and methods 
Cell lines. RFH06N1 and RFAGT1 are 208F recipient cells 
and have been described elsewhere (8,9). They were obtained 
after transfection of normal and T24 BamHI H-ras 1 fragment 
respectively and express high levels of ras p21 protein. 
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Figure 1. Schematic representation of the recombinant plasmid employed as 
competitor in quantification assays. Nucleotide numbering of the competitor 
sequence as per Capon el al (14). The competitor was derived from a 419bp 
PCR product after deletion at position 1853-2040 of an internal fragment 
with Pstl. 
DNA and RNA extraction. DNA was extracted from the cells 
by proteinase Κ (Boehringer) and phenol/chloroform 
treatment as previously described (10). RNA was extracted 
by the RNazolB kit (China-Biotex) as previously described 
(5). The quality and quantity of RNA and DNA was assessed 
by spectrophotometry at 260 nm and 280 nm. 
Recombinant Η-ras plasmid. The transcription vector pGEM-
AH-ras was engineered by cloning a 232bp fragment into the 
Sail site of pGEM4 (Promega). The 232bp fragment was 
derived from a genomic DNA PCR product after internal 
deletion of 187bp with Pstl (NEB) Fig. 1. 
In vitro transcription. The transcription plasmid pGEM-ΔΗ-
ras was linearized with EcoRI so as to yield RNA of about 
295 bp. Following in vitro transcription with T7 RNA 
polymerase (Gibco-BRL) RNA was purified as previously 
described and assessed qualitatively by agarose gel 
electrophoresis and spectrophotometry. 
PCR amplification. PCR amplification was performed in 50 
μΐ reactions (75 mM Tris-HCl pH 9.0, 20 mM (NH4)2S04, 
1.5 mM MgCl2, 0.01% Tween (w/v), 200 μΜ dNTPs) with 
100 ng of each primer and 0.25U Taq polymerase (Advanced 
Biotechnologies). The amplimer sequences were: 
5'-GACGGAATATAAGCTGGTGG-3' and 
5'-AGGCACGTCTCCCCATCAAT-3'. 
The PCR program consisted of 50 sec at 94°C, 35 sec at 62°C 
and 35 sec at 72°C for a total of 25 cycles. 
RT-PCR amplification. Reverse transcription was performed 
in a 50 μΐ reaction (10 mM Tris-HCl pH 8.3, 50 mM KCl, 1 
mM MnCl2, 200 μΜ dNTPs) with 200 ng of antisense primer 
and 2.5U Tth polymerase. The reactions were incubated at 
70°C for 10-15 min. PCR amplification of cDNA was 
performed by supplementing 50 μΐ of: 75 mM Tris-HCl pH 
9.0, 20 mM (NH4)2S04, 1.5 mM MgCl2, 0.01% Tween (w/v), 
0.75 mM EGTA and 200 ng of sense primer to the RT 
reaction, following the same PCR program as described 
above. 
RFLP analysis. 15 μΐ of the PCR reactions were subjected to 
Mspl (NEB) digestion (20U) at a final volume of 30 μΐ at 
37°C for 4 h. The products were electrophoresed through a 
3% agarose gel (BRL). Gels were stained with ethidium 
bromide and photographed on an ultraviolet transilluminator. 
DNA quantitation. 100 ng of genomic DNA (from RFAGT1 
and RFH06N1 cell lines) were mixed with tenfold 
sequentially diluted EcoRI linearized pGEM-AH-ras plasmid 
(5 ng, 500 pg, 50 pg, 5 pg, 0.5 pg) respectively. PCR 
amplification was performed as previously described. 
Products were separated on 6% Polyacrylamide gels and 
silver stained. Gels were scanned on a Personal 
Densitometer™ SI (Molecular Dynamics) (11). Data 
obtained from densitometric analysis were statistically 
analysed on a Macintosh computer with Cricket Graph (ver. 
1.3.2). 
RNA quantitation. Total RNA from RFAGT1 and RFH06N1 
cell lines was twofold serially diluted (1 μg, 0.5 μg, 0.25 μg, 
0.1 μg, 0.05 μg) respectively and mixed with 0.1 ng (6.4x108 
copies) cRNA. RT-PCR was performed as previously 
described. Products were run on 6% Polyacrylamide gel and 
silver stained. Densitometric and statistical analysis were 
performed as for DNA quantitation. 
Results 
PCR amplification. For the specific detection and 
amplification of H-ras transcripts, a pair of primers was 
designed using an exon connection strategy. The amplified 
cDNA segment is of 151 bp and consists of exon 1 and the 5' 
end of exon 2 (Fig. 2B, 2D). The same primer pair enables 
amplification from genomic DNA, but yields a different 
sized product of 419 bp, since the intervening intron is also 
amplified (Fig. 2A, 2C). Thus after RT-PCR amplification it 
is also possible to check for the presence of contaminating 
DNA in the RNA preparations. 
Detection of codon 12 mutations. Detection of codon 12 
mutations is accomplished by the use of a natural occurring 
RFLP in the PCR products of the normal and mutated gene 
and transcripts. In normal H-ras 1 alleles, codon 12 is part of 
a Mspl restriction site. Mutations at codon 12 inactivate this 
Mspl site, allowing discrimination of mutant alleles from 
wild type H-rasl alleles (Fig. 2). A second natural Mspl site 
at the 3' end of PCR products, present in both cDNA as well 
as genomic DNA, is conserved and serves as a control for the 
efficiency of digestion at the 5' end site, discriminating at the 
same time the digested products from the undigested ones 
(Fig. 2). 
PCR amplification of H-rasl cDNA as well as genomic 
DNA from the RFAGT1 and RFH06N1 cell lines resulted in 
the expected product sizes respectively (Fig. 2). Under the 
same conditions RNA and DNA from the parental cell line 
208F showed negative results demonstrating the high 
specificity of the primers for the human sequence. 
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Figure 2. Schematic representation of Η-ras DNA and cDNA amplicons 
before and after RFLP analysis. A. Undigested DNA amplicons are 419bp in 
size while normal and mutant Η-ras RFLP products are 354bp and 385bp 
respectively. B. For cDNA amplicons the equivalent sizes are: 151bp for 
undigested PCR product, 117bp for mutant H-ra.ç RFLP product and 86bp 
for normal H-ra.v RFLP product. C. and D. Representative results of 
application of the RT-PCR-RFLP and PCR-RFLP assays from the 
RFH06N1 and RFAGT1 cell lines. Cl= normal Η-ras DNA amplicon, C2= 
undigested DNA amplicon, C3= mutant U-ras DNA amplicon, Dl= normal 
Η-ras cDNA amplicon, D2= undigested cDNA amplicon, D3= mutant Li­
rai cDNA amplicon, M=marker. 
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Figure 3. Comparative quantitation results for H-ras copy number present in 
the genomes of RFH06N1 and RFAGTl cell lines. A. Log plots of PCR 
products versus tenfold serial dilutions of competitor vector (5 ng-0.5 pg). 
The RFH06N1 cell line exhibited approximately 7-fold higher number of 
H-ra.v copies in the genome than RFAGTl cells. B. and C. Representative 
results from quantitative PCR assays for RFH06N1 (panel B) and RFAGTl 
(panel C) cells. M=marker, lanes 1-5=5 ng-0.5 ng competitor vector/ 100 ng 
genomic DNA. 
RFLP analysis of genomic DNA amplicons from 
RFH06N1 revealed the presence of only normal human fi-
rasi alleles, while in the RFAGTl cell line only mutant H-
rasl was detected (Fig. 2). In addition RFLP analysis of 
cDNA amplicons showed the expression of the specific ti­
ras type present in each cell line. 
Quantitation by ratio. To obtain quantitative measurements 
of H-rasl gene and transcript copies, a competitive assay 
was employed. An internal control was constructed and 
cloned in an expression vector. The internal control was 
derived from a genomic DNA PCR product after internal 
deletion with PstI of a 187 bp fragment (Fig. 1) (12). Despite 
the difference in size, the internal control has the same 
primer annealing sites as H-rasl cDNA and genomic DNA 
enabling competitive PCR reactions to be performed. 
i) The construct itself was employed in genomic DNA 
quantitation assays for the determination of H-rasl copy 
number present in each cell line. Tenfold dilution series of 
Plasmid DNA were prepared over a large input range of 5 ng 
to 0.5 pg and spiked separately with 100 ng of genomic DNA 
from each cell line. 
The log ratios of densitometric values of competitor to 
genomic DNA after PCR amplification were plotted against 
the log values of diluted construct amounts. Regression 
analysis showed that the data fit closely with linear lines in 
both cell lines (Fig. 3). The linear relationships were 
preserved over a wide range of PCR cycle numbers, but in 
order to keep the slopes of the equations closer to unity as 
predicted by the theoretical analysis of PCR amplification 
(13), the optimum conditions described in Methods were 
employed. 
The equations for the standard curves of RFH06N1 and 
RFAGTl cell lines were y=0.71x-0.72 (R2=0.98) and 
y=0.72x-0.12 (R2=0.99) respectively. From the equivalence 
points (y=0) for each cell line it was estimated that the 
RFH06N1 cell line (6.3x10" copies/100 ng genomic DNA) 
had received approximately 7-fold higher copy number of H-
ras than the RFAGTl cell line (91.5xl04 copies/100 ng 
genomic DNA). 
ii) In order to obtain similar data at the RNA level run-off 
transcripts were obtained after in vitro transcription from the 
recombinant vector (as described in Methods). Two-fold 
serial dilution series of totRNA from each cell line was 
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Figure 4. Comparative quantitation results for H-ra.vl transcriptional 
expression level of RFH06N1 and RFAGT1 cell lines. A. Log plots of 
twofold serially diluted totRNA (1 μg-0.05 μ§) versus 100 pg (6.4x108 
copies) cRNA. The level of expression of U-ras is higher in RFH06N1 cells 
since 7.5-fold higher amount of totRNA from RFAGT1 cells is necessary to 
obtain similar level of Η-ras transcripts as per RFH06N1 cells. B. and C. 
Representative results from quantitative RT-PCR assays for RFH06N1 
(panel B) and RFAGT1 (panel C) cells. M=marker, lanes 1-5=1 μg-0.05 μg 
totRNA/lOOpgcRNA. 
prepared in the range of 1 μ§-0.05 μg. The serial dilutions 
were spiked with 100 pg of cRNA and the mixtures were 
subjected to RT-PCR amplification. 
Graphical representations of log-log plots were obtained 
and linear regression analysis was performed (Fig. 4). Linear 
relationship was observed over a wide range of PCR cycle 
numbers, but in order to keep the slope of the equations close 
to unity high PCR cycling numbers were avoided so as to 
keep the reactions in the log phase of amplification. 
The standard curves for RFH06N1 and RFAGT1 cell 
lines were y=1.17x-1.47 (R2=0.99) and y=1.09x-2.33 
(R2=0.99) respectively. From the equivalence points of the 
equations it was estimated that the level of H-rasl transcripts 
was approximately 7.5-fold higher in RFH06N1 (3.5xl012 
copies/ μg totRNA) than in RFAGT1 (0.46xl012 copies/ μg 
totRNA) cells. This result is in agreement with the difference 
in the copy number of H-rasl present in the genome of each 
cell line. 
Discussion 
We have described a PCR based method to enable 
investigation of H-rasl alterations both at genomic and 
transcriptional level. Our aim is to detect qualitative as well 
as quantitative changes in H-rasl function in tumours. 
Point mutational activation of the H-rasl gene is known 
to be an early event in the pathology of certain tumours ( 1 -3). 
The presence of such mutations can be detected by exploiting 
natural RFLP sites present at the nucleotide level of H-rasl 
(6,14). We have designed the primers described in this report 
with the following in mind: 
i) Potential detection of cDNA and genomic DNA H-rasl 
amplicons by the same pair of primers. The exon connection 
strategy employed for the detection of H-rasl amplicons 
enables discrimination from the genomic DNA amplicons 
due to the presence of the intervening intron. Thus, both 
types of PCR products can easily be distinguished by size 
fractionation after electrophoresis. 
ii) RFLP detection of codon 12 mutation in both H-rasl 
amplicon types. The primers were designed in order to 
preserve and make use of the existing natural Mspl site 
which includes codon 12. Furthermore, the antisense primer 
was positioned downstream of a second Mspl site which is 
conserved in the H-rasl nucleotide sequence. The second 
restriction site provides a control for efficient enzyme 
digestion as well as discrimination of RFLP products from 
undigested PCR products (6,7). Preservation of both 
restriction sites in RT-PCR products as well as in the PCR 
products allows detection of expression of normal and 
activated H-rasl transcripts. 
The two rodent cell lines employed as controls in this 
work, behaved exactly as expected according to the type of 
human H-rasl introduced into their genomes. RFLP analysis 
at genomic and transcriptional level provided equivalent 
results. 
Recently it has been shown that structural modifications 
are followed by allelic imbalances (5) or altered ratio of 
expression between normal and mutant H-rasl transcripts 
(6). In order to evaluate such quantitative alterations both at 
DNA and RNA level we have designed an internal 
competitor with a different size, to be coupled to 
amplification reactions. The internal control was cloned in an 
expression vector, to provide cRNA transcripts suitable to be 
used in the RT reaction step. The use of an internal 
competitor in the RT step provides more accurate control for 
the overall reaction efficiency during quantification 
reactions. On the other hand the construct itself can be 
employed in DNA quantifications of H-rasl gene copies. 
The comparison between gene copy number and 
transcriptional expression level could provide answers for the 
expressional activation of H-rasl. 
The cell lines used in this study were previously known to 
harbour high copy numbers of normal and mutant H-rasl 
gene respectively (8,9). For this reason these cell lines were 
suitable to create the situation where high copy numbers 
present in the genome result in high levels of gene 
expression. 
We performed the quantitative assays described to test the 
efficacy and accuracy of competitive (RT-)PCR estimations. 
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Quantitative analysis of data gathered from the cell line 
measurements show a linear relationship between the ratio of 
amplified products and the initial concentrations of the 
substrates. This is confirmed by the high values of the 
correlation coefficient (R 2=0.98-0.99) obtained after 
regression analysis of each set of data. Theoretical analysis 
however argues that this kind of relationship is not sufficient 
for the product ratio to reflect the real ratio between the 
target and competitor molecule (13). According to the 
mathematical modelling of the reaction equation, in addition 
to the linear relationship of the data it is necessary for the 
slope of the equation to be equal to unity (13). This results in 
minimisation of error estimation of initial concentrations 
after extrapolating the product ratio on the standard curve 
(13). 
We have obtained quantitative data sets for varying PCR 
cycles which invariably show a linear relationship, but 
usually with a slope deviating from unity. In our experience 
the closest values to unity of the slope were obtained after 
low PCR cycling numbers (£25), although the accumulated 
PCR products were scarcely seen on ethidium bromide 
stained agarose gels (15), making direct densitometric 
analysis of the gels difficult (16). For this reason we chose 
direct densitometric analysis of silver stained Polyacrylamide 
gels (11,16). 
The standard curves describing the linear quantitative 
relationship of the serial dilutions series versus product ratios 
exhibited an identical slope at DNA or RNA level between 
the two cell lines respectively. This can be explained by the 
same primer efficiency during assay performance of either 
RT-PCR or PCR, for each cell line respectively. This parallel 
shift between the data of the two cell lines is in agreement 
with theoretical considerations (13). 
The most accurate measurements were obtained by 
quantification closer to the equivalence points (13). 
Increasing the quantification range around the stoichiometric 
point preserved linearity but altered the slope of the curve 
(13). This was observed in the case of RNA quantitation 
where the total RNA varied over a 20-fold range in contrast 
to DNA where a 104-fold range was used. Furthermore PCR 
amplification of cDNA has been reported to be less efficient 
than DNA amplification (17). 
Finally, we draw attention to the experimental conditions 
necessary to perform competitive assay quantification, since 
this approach has been described as the most accurate 
approach to PCR quantitation (18). Experimental conditions 
need to be established carefully and standardised for each 
specific application to satisfy the theoretical conditions 
inferred by mathematical analysis of competitive 
quantitation. These should include competitor design and 
experimental conditions during PCR (or RT-PCR) 
amplification. 
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